Expanding COVID-19 Assays EpigenTek has demonstrated its agility by launching SARS-CoV-2 research assays and rapid serological tests during the COVID-19 pandemic, highlighting opportunities to provide specialized epigenetic solutions for infectious disease research and diagnostics markets.

Broad Global Reach With products distributed across more than thirty-six countries through a dedicated sales force and network of distributors, EpigenTek offers partners the chance to expand sales into diverse international markets focused on epigenetics research and clinical applications.

Innovative Product Portfolio The company's focus on continuously developing faster, simpler, and more efficient epigenetic assay kits creates opportunities to upsell to existing clients and attract new research institutions and biotech firms seeking cutting-edge technologies.

Collaborative Opportunities The collaboration with EpigenCare for personalized skincare based on epigenetic markers indicates potential for business development in consumer health markets, personalized medicine, and dermatology sectors.

Growth in Epigenetic Research EpigenTek’s ongoing innovation in epigenetics and genome-wide analysis kits aligns well with the growing demand for epigenetic understanding in drug discovery and biomarker development, presenting clear sales prospects with academic and pharmaceutical clients.